Haruo Inokuchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Haruo Inokuchi has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Fumiaki Isohashi
Department of Radiation Oncology Nara Medical University Kashihara Nara Japan
1 shared publication - Hidenori Shinjo
Department of Radiation Oncology, Showa University Hospital, Tokyo, Japan
1 shared publication - Hiroyuki Okamoto
Section of Radiation Safety and Quality Assurance, National Cancer Center Hospital , 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045
1 shared publication - Ken Ando
Department of Radiation Oncology, Gunma University Graduate School of Medicine, Maebashi, Japan
1 shared publication - Koji Horie
Department of Gynecology, Saitama Cancer Center, Saitama 362-0806, Japan
1 shared publication - Mamiko Onuki
Department of Obstetrics and Gynecology, Showa University, Tokyo, Japan
1 shared publication
Latest Publications
- Open Access
- 22 December 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (5) , 575-582
A multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors
The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.
- 22 December 2018
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 24 (5) , 575-582
Open AccessA multi-institutional observational study on the effects of three-dimensional radiotherapy and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors
The aim of this study was to evaluate the effects of treatment with both three-dimensional radiotherapy (3DRT) and weekly 40-mg/m2 cisplatin on postoperative uterine cervical cancer patients with high-risk prognostic factors.